349 related articles for article (PubMed ID: 8615179)
1. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy.
Melamed E; Zoldan J; Friedberg G; Ziv I; Weizmann A
Adv Neurol; 1996; 69():545-50. PubMed ID: 8615179
[No Abstract] [Full Text] [Related]
2. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
Greene P; Cote L; Fahn S
Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
[No Abstract] [Full Text] [Related]
3. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
Zoldan J; Friedberg G; Weizman A; Melamed E
Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178
[No Abstract] [Full Text] [Related]
4. [Hallucinations in Parkinson's disease].
Moser A; Hagenah J; Kömpf D
Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
[TBL] [Abstract][Full Text] [Related]
5. What to do when Sinemet fails: Part one.
Klawans HL
Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
[No Abstract] [Full Text] [Related]
6. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
7. Zotepine in levodopa-induced Psychosis.
Spieker S; Stetter F; Klockgether T
Mov Disord; 1995 Nov; 10(6):795-7. PubMed ID: 8750001
[No Abstract] [Full Text] [Related]
8. [Levodopa dependency in Parkinson's disease: case report and review].
Müller U; Reuter M; Hermann W; Gertz HJ
Nervenarzt; 2002 Sep; 73(9):887-91. PubMed ID: 12215883
[TBL] [Abstract][Full Text] [Related]
9. [Psychiatric complications of L-dopa: physiopathology and treatment].
Castro-García A
Rev Neurol; 1997 Aug; 25 Suppl 2():S157-62. PubMed ID: 9280683
[TBL] [Abstract][Full Text] [Related]
10. Suicide following duodenal levodopa infusion for Parkinson's disease.
Santos-García D; Macías M; Llaneza M; Aneiros A
Mov Disord; 2009 Oct; 24(13):2029-30. PubMed ID: 19645071
[No Abstract] [Full Text] [Related]
11. Opioids and motor complications in Parkinson's disease.
Samadi P; Bédard PJ; Rouillard C
Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
[TBL] [Abstract][Full Text] [Related]
12. [Levodopa-induced psychosis in patients with idiopathic Parkinson disease].
García-Escrig M; Bermejo Pareja F; Fernández Ponsatí JT
Med Clin (Barc); 1999 Feb; 112(7):245-50. PubMed ID: 10220750
[TBL] [Abstract][Full Text] [Related]
13. Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease.
Rosenthal SH; Fenton ML; Harnett DS
Gen Hosp Psychiatry; 1992 Jul; 14(4):285-6. PubMed ID: 1505751
[No Abstract] [Full Text] [Related]
14. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
15. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
16. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
Rascol O
Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400
[No Abstract] [Full Text] [Related]
17. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
Klivényi P; Vécsei L
Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
[TBL] [Abstract][Full Text] [Related]
18. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine.
Normann C; Hesslinger B; Frauenknecht S; Berger M; Walden J
Pharmacopsychiatry; 1997 Nov; 30(6):263-5. PubMed ID: 9442549
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and therapy of Parkinson's disease].
Wittstock M; Benecke R
MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
Cools R
Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
